Compare AbbVie Inc (ABBV) vs Monster Beverage Corp (MNST) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs Monster Beverage Corp — how do they compare? AbbVie Inc trades at $253.61 (market cap $449.91B), while Monster Beverage Corp trades at $95.67 (market cap $94.79B). The key difference: AbbVie Inc is far larger — about 4.7× Monster Beverage Corp's market cap, and AbbVie Inc pays a 2.72% dividend while Monster Beverage Corp pays none. Which is the better fit depends on your goals.
| ABBV | MNST | |
|---|---|---|
Market Cap | $449.91B | $94.79B |
Sector | Health | Consumer Staples |
52-Week High | $261.07 | $97.64 |
52-Week Low | $184.85 | $58.65 |
Enterprise Value | $513.38B | $93.08B |
Dividend Yield | 2.72% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $252.92, down 0.72% on the day, with strong technical support at $251 and resistance at $258. The stock shows bullish momentum with recent earnings beats and a consensus analyst price target of $266.33. Revenue grew to $61.16B in 2025, though net margins compressed to 5.79%. Key growth drivers include Skyrizi and Rinvoq offsetting Humira declines, supported by positive Phase 2 data for ELAHERE in ovarian cancer (PRNewsWire, 2026-04-12).
Outlook remains positive with immunology portfolio strength and dividend growth, but risks include patent cliffs in the 2030s and high debt levels. Institutional buying and 68% analyst buy ratings suggest confidence, though valuation multiples like P/E of 124.83 warrant caution. Near-term catalysts include Q2 2026 earnings expected at $3.79 EPS.
Monster Beverage (MNST) trades at $96.92, down 0.7% on the day, with strong technical momentum indicated by bullish moving averages. The company demonstrates robust fundamentals with revenue growing from $6.3B in 2022 to $8.3B in 2025 and net income reaching $1.91B. Recent earnings have consistently beaten expectations, with Q1 2026 EPS of $0.58 exceeding the $0.527 forecast. Analyst sentiment remains positive with 53% buy ratings, though valuation metrics appear elevated with a P/E of 47.04.
MNST presents growth opportunities through international expansion and product innovation, with overseas sales reaching 45% of revenue. However, the stock faces risks from premium valuation levels and competitive pressures in the energy drink market. The consensus price target of $91.67 suggests potential downside from current levels, while technical indicators show the stock trading near resistance at $98-$100.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Monster Beverage Corp
Monster Beverage is a leader in the energy drink subsegment of the beverage industry. The Monster trademark anchors the portfolio, and notable offerings include Monster Energy and Monster Ultra. The firm has also started to incubate new trademarks for emerging enclaves of the energy space, like Reign in performance energy. It is primarily a brand owner, outsourcing most of its manufacturing processes to third-party copackers. It primarily uses the Coca-Cola bottling system for distribution after a strategic agreement in which Coke became Monster's largest shareholder (nearly 20%) and that also included the exchange of certain businesses between the two firms. Most of Monster's revenue is generated in the United States, though international geographies are increasing in the mix.
Read more on MNST →
